newdrugapprovals.org
FDA approves Pfizer’s Ibrance (palbociclib) for postmenopausal women with advanced breast cancer
PALBOCICLIB Mechanism of action: selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 Indication: Estrogen receptor-positive (ER+), HER2-negative (HER2 -) breast cancer FDA approves Ib…